Prospective Study of the Influence of the Diffuse Noxious Inhibitory Controls of the Pain on the Efficacy of Milnacipran in Fibromyalgia Therapy

NCT01747044 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Fibromylagia

Interventions

DRUG: Milnacipran
DRUG: Placebo

Sponsor

University Hospital, Clermont-Ferrand

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]